TAIM
ALXN

TD Ameritrade Investment Management’s Alexion Pharmaceuticals ALXN Stock Holding History

TD Ameritrade Investment Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-741
Closed -$85K – 742
2021
Q3 		$85K Buy
741
+714
+2,644% +$131K ﹤0.01% 275
2021
Q2 		$5K Sell
27
-637
-96% -$109K ﹤0.01% 535
2021
Q1 		$104K Hold
664
– – ﹤0.01% 267
2020
Q4 		$104K Sell
664
-77
-10% -$9.89K ﹤0.01% 267
2020
Q3 		$85K Buy
741
+154
+26% +$16.6K ﹤0.01% 275
2020
Q2 		$66K Buy
587
+9
+2% +$956 ﹤0.01% 283
2020
Q1 		$52K Buy
578
+97
+20% +$9.52K ﹤0.01% 290
2019
Q4 		$52K Buy
481
+94
+24% +$10.1K ﹤0.01% 313
2019
Q3 		$38K Buy
387
+360
+1,333% +$40.6K ﹤0.01% 317
2019
Q2 		$4K Sell
27
-19
-41% -$2.45K ﹤0.01% 528
2019
Q1 		$6K Sell
46
-1
-2% -$124 ﹤0.01% 434
2018
Q4 		$5K Buy
47
+9
+24% +$1.06K ﹤0.01% 460
2018
Q3 		$5K Buy
38
+30
+375% +$3.76K ﹤0.01% 410
2018
Q2 		$1K Buy
+8
New +$935 ﹤0.01% 456

Other funds holding ALXN

RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

TD Ameritrade Investment Management's ALXN Position: Q4 2021 in Review

TD Ameritrade Investment Management sold out of Alexion Pharmaceuticals (ALXN) in Q4 2021, closing a stake of 741 shares — an estimated $85K sold.

TD Ameritrade Investment Management first reported a position in ALXN in Q2 2018 and held it in 14 quarters. The position peaked at $104K in Q1 2021. 2 funds tracked by Wall St. Rank hold ALXN as of Q4 2021.

  • TD Ameritrade Investment Management reported no remaining Alexion Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • TD Ameritrade Investment Management sold 741 Alexion Pharmaceuticals shares in Q4 2021, an estimated $85K.
  • TD Ameritrade Investment Management first reported a position in Alexion Pharmaceuticals in Q2 2018 and held it in 14 quarters.
  • TD Ameritrade Investment Management's Alexion Pharmaceuticals position peaked at $104K in Q1 2021.
  • 2 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2021.

Based on TD Ameritrade Investment Management's 13F filing for Q4 2021, filed 11 Feb 2022.